What is the difference between triple-negative and basal breast cancers?
- PMID: 20164685
- DOI: 10.1097/PPO.0b013e3181cf04be
What is the difference between triple-negative and basal breast cancers?
Abstract
Triple-negative breast cancer (TNBC) represents a phenotype defined by the lack of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor-2 expression. Because TNBCs have more aggressive features and lack a therapeutic target, they have become a key topic of clinical and research interest within the oncology community. With advancements in the field of molecular biology, gene expression profiling has resulted in the identification of intrinsic subtypes including basal-like breast cancers (BLBCs). Although often thought to be synonymous, TNBC and BLBC represent different biologic phenomena. Furthermore, even within the basal-like subtype, diversity exists. The purpose of this review is to outline the most current evidence in an attempt to answer the question: what is BLBC?
Similar articles
-
Treatment of triple negative breast cancer (TNBC): current options and future perspectives.Cancer Treat Rev. 2010 Nov;36 Suppl 3:S80-6. doi: 10.1016/S0305-7372(10)70025-6. Cancer Treat Rev. 2010. PMID: 21129616 Review.
-
Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice.Adv Anat Pathol. 2007 Nov;14(6):419-30. doi: 10.1097/PAP.0b013e3181594733. Adv Anat Pathol. 2007. PMID: 18049131 Review.
-
Triple-negative/basal-like breast cancer: clinical, pathologic and molecular features.Expert Rev Anticancer Ther. 2010 Feb;10(2):199-207. doi: 10.1586/era.09.189. Expert Rev Anticancer Ther. 2010. PMID: 20131996 Review.
-
Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers.Hum Pathol. 2008 Feb;39(2):167-74. doi: 10.1016/j.humpath.2007.06.012. Epub 2007 Nov 28. Hum Pathol. 2008. PMID: 18045647
-
Epidermal growth factor receptor in triple-negative and basal-like breast cancer: promising clinical target or only a marker?Cancer J. 2010 Jan-Feb;16(1):23-32. doi: 10.1097/PPO.0b013e3181d24fc1. Cancer J. 2010. PMID: 20164687 Review.
Cited by
-
AXL knockdown gene signature reveals a drug repurposing opportunity for a class of antipsychotics to reduce growth and metastasis of triple-negative breast cancer.Oncotarget. 2019 Mar 12;10(21):2055-2067. doi: 10.18632/oncotarget.26725. eCollection 2019 Mar 12. Oncotarget. 2019. PMID: 31007848 Free PMC article.
-
RNF40 epigenetically modulates glycolysis to support the aggressiveness of basal-like breast cancer.Cell Death Dis. 2023 Sep 28;14(9):641. doi: 10.1038/s41419-023-06157-5. Cell Death Dis. 2023. PMID: 37770435 Free PMC article.
-
Down-Regulation of Toll-Like Receptor 5 (TLR5) Increased VEGFR Expression in Triple Negative Breast Cancer (TNBC) Based on Radionuclide Imaging.Front Oncol. 2021 Jul 15;11:708047. doi: 10.3389/fonc.2021.708047. eCollection 2021. Front Oncol. 2021. PMID: 34336694 Free PMC article.
-
Currently Used Laboratory Methodologies for Assays Detecting PD-1, PD-L1, PD-L2 and Soluble PD-L1 in Patients with Metastatic Breast Cancer.Cancers (Basel). 2021 Oct 18;13(20):5225. doi: 10.3390/cancers13205225. Cancers (Basel). 2021. PMID: 34680373 Free PMC article. Review.
-
Reinventing diagnostics for personalized therapy in oncology.Cancers (Basel). 2010 Jun 2;2(2):1066-91. doi: 10.3390/cancers2021066. Cancers (Basel). 2010. PMID: 24281107 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials